EndoGastric Solutions
San Mateo, US · Delaware corporation · 8 known investors
EndoGastric Solutions offers the Transoral Incisionless Fundoplication (TIF 2.0) procedure and the EsophyX device used to treat GERD, along with reimbursement and technical/administrative support (TAP program) for medical practices. The company, now associated with Merit Medical, serves gastroenterology and surgical providers performing anti-reflux procedures.
BiotechHealthtechMedical Devices
Founders & leadership
PM
Philip MacdonaldExecutive
LB
Louis BaldinoExecutive
LL
Lilip LauNamed on SEC filing
GJ
Guy JordanNamed on SEC filing
FL
Floyd Loop, M.D.Named on SEC filing
JD
Josh DeFonzoNamed on SEC filing
RM
Robert Michael KleineNamed on SEC filing
Board
MC
AM
Arda MinocherhomjeeBoard director
BA
JD
Jordan DavisBoard director
LW
Lee Wrubel, M.D.Board director
Investors · 8
Reported raises · per SEC filings
Form D private placements$110.6M disclosed across 6 rounds · 2014–2020
▶$27MraisedDec 2021 · 32 investors · Other Health CareRule 506(b)
▶$27MraisedDec 2021 · 32 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Louis BaldinoExecutive Officer, Director
- Darren CrowExecutive Officer
- Michael CarusiDirector
- Theodore StephensExecutive Officer
- Brent AhrensDirector
- Alejandro SanchezDirector
- John GillingsDirector
- Michael BurkeExecutive Officer
- Kunal PaymasterDirector
- Martin ReidExecutive Officer
- Offering amount
- $45M
- Amount sold
- $27M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.6MraisedJun 2019 · 31 investors · Other Health CareRule 506(b)
▶$40.6MraisedJun 2019 · 31 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Arda MinocherhomjeeDirector
- Uri GeigerDirector
- Theodore StephensExecutive Officer
- Martin ReidExecutive Officer
- Darren CrowExecutive Officer
- Michael BurkeExecutive Officer
- Louis BaldinoExecutive Officer, Director
- Philip MacdonaldExecutive Officer
- Jordan DavisDirector
- Brent AhrensDirector
- Kunal PaymasterDirector
- Alejandro SanchezDirector
- Michael CarusiDirector
- Offering amount
- $40.6M
- Amount sold
- $40.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedMay 2015 · 17 investors · BiotechnologyRule 506(b)
▶$10MraisedMay 2015 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael CarusiDirector
- Scott WardDirector
- Arda MinocherhomjeeDirector
- Philip MacdonaldExecutive Officer
- Brent AhrensDirector
- Jordan DavisDirector
- Lee Wrubel, M.D.Director
- Louis BaldinoExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $10M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedApr 2015 · 13 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2015 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael CarusiDirector
- Scott WardDirector
- Skip BaldinoExecutive Officer, Director
- Arda MinocherhomjeeDirector
- Jordan DavisDirector
- Brent AhrensDirector
- Philip MacdonaldExecutive Officer
- Lee Wrubel, M.D.Director
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- Minimum investment
- $1.8K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.6MraisedMay 2014 · 16 investors · BiotechnologyRule 506(b)
▶$30.6MraisedMay 2014 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guy JordanDirector
- Scott WardDirector
- Robert Michael KleineDirector
- Arda MinocherhomjeeDirector
- Brent AhrensDirector
- Lilip LauExecutive Officer
- Jordan DavisDirector
- Lee Wrubel, M.D.Director
- Josh DeFonzoExecutive Officer
- Skip BaldinoExecutive Officer
- Floyd Loop, M.D.Director
- Michael CarusiDirector
- Offering amount
- $30.7M
- Amount sold
- $30.6M
- Minimum investment
- $33.9K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedApr 2014 · 14 investors · BiotechnologyRule 506(b)
▶$1MraisedApr 2014 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael CarusiDirector
- Lilip LauExecutive Officer
- Scott WardDirector
- Guy JordanDirector
- Floyd Loop, M.D.Director
- Josh DeFonzoExecutive Officer
- Arda MinocherhomjeeDirector
- Brent AhrensDirector
- Lee Wrubel, M.D.Director
- Jordan DavisDirector
- Robert Michael KleineDirector
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $3.2K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does EndoGastric Solutions do?
- EndoGastric Solutions offers the Transoral Incisionless Fundoplication (TIF 2.0) procedure and the EsophyX device used to treat GERD, along with reimbursement and technical/administrative support (TAP program) for medical practices. The company, now associated with Merit Medical, serves gastroenterology and surgical providers performing anti-reflux procedures.
- Who are EndoGastric Solutions's investors?
- EndoGastric Solutions's investors include Accelmed Partners, Canaan Partners, Evidity Health Capital, Lightstone Ventures, VCFA Group, De Novo Ventures, FOUNDATION MEDICAL PARTNERS, SightLine Partners.
- How much funding has EndoGastric Solutions raised?
- EndoGastric Solutions has disclosed $110.6M raised across 6 rounds.
- Where is EndoGastric Solutions headquartered?
- EndoGastric Solutions is headquartered in San Mateo, US.